Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | HPGDS | O60760 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23711756 | 1.00 | KHK (1.00) | KHKTP53HPGDSHPGDMAPT | |
| SCHEMBL23711773 | 0.90 | KHK (1.00) | KHKTP53HPGDSHPGDMAPT | |
| SCHEMBL31279149 | 0.90 | KHK (1.00) | KHKTP53HPGDSHPGDMAPT | |
| SCHEMBL31279611 | 0.89 | KHK (1.00) | KHKHPGDSMAPK14ACSS2 | |
| SCHEMBL23711737 | 0.89 | KHK (1.00) | KHKHPGDSMAPK14ACSS2 | |
| SCHEMBL23711755 | 0.82 | KHK (0.79) | KHKTP53HPGDSMAPK14ACSS2 | |
| SCHEMBL31279847 | 0.82 | KHK (0.79) | KHKTP53HPGDSMAPK14ACSS2 | |
| SCHEMBL23711768 | 0.81 | KHK (0.67) | KHKTP53HPGDNPC1RAB9A | |
| SCHEMBL31278857 | 0.81 | KHK (0.67) | KHKTP53HPGDNPC1RAB9A | |
| SCHEMBL23711723 | 0.78 | KHK (1.00) | KHKHPGDSMAPK14ACSS2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177348-A1 | Methods for Fructokinase Meditation of Alcohol Craving and Alcohol Induced Liver Disease | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-06-05 | — | — | US | disclosed |
| US-12161621-B2 | Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2024-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12161621-B2 | Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease | KHK, GCK, FN3K | KHK 1/4885TP53 4864/4885HPGDS 3010/4885 |
| US-20250177348-A1 | Methods for Fructokinase Meditation of Alcohol Craving and Alcohol Induced Liver Disease | KHK, GCK, FN3K | KHK 1/4885TP53 4753/4885HPGDS 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.